House Committee Calls On EPO Marketers To Provide Information, Halt DTC Ads
This article was originally published in The Pink Sheet Daily
Inquiry also requests Amgen and Johnson & Johnson cease financial incentives to physicians.
You may also be interested in...
Labeling for Amgen’s Aranesp and Epogen and Johnson & Johnson’s Procrit updated March 9 to include a black box warning on risk of mortality.
Erythropoietin marketers J&J and Amgen will participate in an FDA Oncologic Drugs Advisory Committee meeting in May.
The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.